Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).

Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M, Olapade O, Yau C, Berry D, Esserman LJ; I-SPY TRIAL Investigators.

Breast Cancer Res Treat. 2012 Apr;132(3):871-9. doi: 10.1007/s10549-011-1670-4. Epub 2011 Jul 28.

2.

Interval breast cancers: absolute and proportional incidence and blinded review in a community mammographic screening program.

Carbonaro LA, Azzarone A, Paskeh BB, Brambilla G, Brunelli S, Calori A, Caumo F, Malerba P, Menicagli L, Sconfienza LM, Vadalà G, Brambilla G, Fantini L, Ciatto S, Sardanelli F.

Eur J Radiol. 2014 Feb;83(2):e84-91. doi: 10.1016/j.ejrad.2013.11.025. Epub 2013 Dec 6.

PMID:
24369953
3.

Regular screening mammography before the diagnosis of breast cancer reduces black:white breast cancer differences and modifies negative biological prognostic factors.

Grabler P, Dupuy D, Rai J, Bernstein S, Ansell D.

Breast Cancer Res Treat. 2012 Sep;135(2):549-53. doi: 10.1007/s10549-012-2193-3. Epub 2012 Aug 12.

PMID:
22886477
4.

Mammographic features associated with interval breast cancers in screening programs.

Boyd NF, Huszti E, Melnichouk O, Martin LJ, Hislop G, Chiarelli A, Yaffe MJ, Minkin S.

Breast Cancer Res. 2014 Aug 26;16(4):417. doi: 10.1186/s13058-014-0417-7.

5.

Mammographic density and survival in interval breast cancers.

Eriksson L, Czene K, Rosenberg LU, Törnberg S, Humphreys K, Hall P.

Breast Cancer Res. 2013 Jun 20;15(3):R48. doi: 10.1186/bcr3440.

6.

Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2007;7(1):1-32. Epub 2007 Jan 1.

7.

Age of diagnosis, tumor size, and survival after breast cancer: implications for mammographic screening.

Narod SA.

Breast Cancer Res Treat. 2011 Jul;128(1):259-66. doi: 10.1007/s10549-010-1318-9. Epub 2011 Jan 4.

PMID:
21203901
8.

Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program.

Kirsh VA, Chiarelli AM, Edwards SA, O'Malley FP, Shumak RS, Yaffe MJ, Boyd NF.

J Natl Cancer Inst. 2011 Jun 22;103(12):942-50. doi: 10.1093/jnci/djr138. Epub 2011 May 3.

PMID:
21540443
9.

Digital compared to screen-film mammography: breast cancer prognostic features in an organized screening program.

Prummel MV, Done SJ, Muradali D, Majpruz V, Brown P, Jiang H, Shumak RS, Yaffe MJ, Holloway CM, Chiarelli AM.

Breast Cancer Res Treat. 2014 Sep;147(2):389-99. doi: 10.1007/s10549-014-3088-2. Epub 2014 Aug 10.

PMID:
25108740
10.

A failure analysis of invasive breast cancer: most deaths from disease occur in women not regularly screened.

Webb ML, Cady B, Michaelson JS, Bush DM, Calvillo KZ, Kopans DB, Smith BL.

Cancer. 2014 Sep 15;120(18):2839-46. doi: 10.1002/cncr.28199. Epub 2013 Sep 9.

11.

Biennial versus annual mammography and the risk of late-stage breast cancer.

White E, Miglioretti DL, Yankaskas BC, Geller BM, Rosenberg RD, Kerlikowske K, Saba L, Vacek PM, Carney PA, Buist DS, Oestreicher N, Barlow W, Ballard-Barbash R, Taplin SH.

J Natl Cancer Inst. 2004 Dec 15;96(24):1832-9.

PMID:
15601639
12.

Clinical and self breast examination remain important in the era of modern screening.

Ma I, Dueck A, Gray R, Wasif N, Giurescu M, Lorans R, Pizzitola V, Pockaj B.

Ann Surg Oncol. 2012 May;19(5):1484-90. doi: 10.1245/s10434-011-2162-9. Epub 2011 Dec 8.

PMID:
22160521
13.

A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer.

Meshkat B, Prichard RS, Al-Hilli Z, Bass GA, Quinn C, O'Doherty A, Rothwell J, Geraghty J, Evoy D, McDermott EW.

Breast. 2015 Jun;24(3):278-82. doi: 10.1016/j.breast.2015.02.032. Epub 2015 Mar 11.

PMID:
25771080
14.

Performance of first mammography examination in women younger than 40 years.

Yankaskas BC, Haneuse S, Kapp JM, Kerlikowske K, Geller B, Buist DS; Breast Cancer Surveillance Consortium.

J Natl Cancer Inst. 2010 May 19;102(10):692-701. doi: 10.1093/jnci/djq090. Epub 2010 May 3.

15.

Impact of false-positive mammography on subsequent screening attendance and risk of cancer.

McCann J, Stockton D, Godward S.

Breast Cancer Res. 2002;4(5):R11. Epub 2002 Jul 17.

16.

Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study.

Zahl PH, Gøtzsche PC, Mæhlen J.

Lancet Oncol. 2011 Nov;12(12):1118-24. doi: 10.1016/S1470-2045(11)70250-9. Epub 2011 Oct 11.

PMID:
21996169
17.

Prognosis in women with interval breast cancer: population based observational cohort study.

Kalager M, Tamimi RM, Bretthauer M, Adami HO.

BMJ. 2012 Nov 16;345:e7536. doi: 10.1136/bmj.e7536.

18.

Impact of the transition from screen-film to digital screening mammography on interval cancer characteristics and treatment - a population based study from the Netherlands.

Nederend J, Duijm LE, Louwman MW, Coebergh JW, Roumen RM, Lohle PN, Roukema JA, Rutten MJ, van Steenbergen LN, Ernst MF, Jansen FH, Plaisier ML, Hooijen MJ, Voogd AC.

Eur J Cancer. 2014 Jan;50(1):31-9. doi: 10.1016/j.ejca.2013.09.018. Epub 2013 Oct 25.

PMID:
24275518
19.

Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers.

Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, Cousens L, White D, Taplin S, White E.

J Natl Cancer Inst. 1999 Dec 1;91(23):2020-8.

PMID:
10580027
20.

Two-view versus single-view mammography at subsequent screening in a region of the Dutch breast screening programme.

van Breest Smallenburg V, Duijm LE, den Heeten GJ, Groenewoud JH, Jansen FH, Fracheboud J, Plaisier ML, van Doorne-Nagtegaal HJ, Broeders MJ.

Eur J Radiol. 2012 Sep;81(9):2189-94. doi: 10.1016/j.ejrad.2011.07.015. Epub 2011 Sep 8.

PMID:
21906898

Supplemental Content

Support Center